english.prescrire.org > Spotlight > 100 most recent > Faricimab (Vabysmo°) in age-related macular degeneration or diabetic macular oedema

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Faricimab (Vabysmo°) in age-related macular degeneration or diabetic macular oedema

 Marketing Authorisations   Faricimab is a monoclonal antibody that simultaneously targets 2 proteins involved in angiogenesis: vascular endothelial growth factor (VEGF) and angiopoietin-2. It has been authorised in the European Union for intravitreal use in adults with neovascular (wet) age-related macular degeneration and in adults with loss of visual acuity due to diabetic macular oedema. What advantages does faricimab offer over VEGF inhibitors in these clinical situations? And what are its adverse effects?
Full article available for download by subscribers

EDITORS' OPINION
Hypothetical

The drug of choice for patients with age-related macular degeneration is generally a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein with a role in angiogenesis. The hypothesis that it might be more effective to target two proteins involved in angiogenesis than one is plausible, but hypothetical benefits are not always confirmed by the clinical evaluation data... 

Full text available for download by subscribers

©Prescrire 1 June 2024

Source: "Faricimab (Vabysmo°) in age-related macular degeneration or diabetic macular oedema" Prescrire Int 2024; 33 (260): 147. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter

Subscribe now

See also:

"Brolucizumab - Beovu°
and age-related macular
degeneration"
Prescrire Int 2021;
30 (226): 120.
Subscribers only

"Brolucizumab (Beovu°) in
diabetic macular oedema"
Prescrire Int 2024;
33 (256): 43.
Subscribers only


Read more:

This month's contents

All the subjects in
Prescrire's spotlight